Aclarion, Inc. (ACON) stock analysis
Healthcare · Health Information Services
From the 10-K filed 2026-03-18
Business type: Asset play
How it makes money
It sells diagnostic software to imaging centers and physicians, but revenue depends on securing reimbursement coverage from insurance companies for its specific procedure codes.
It provides a software-as-a-service platform that analyzes MRI signals to identify painful spinal discs. Because this is a diagnostic tool, physicians and imaging centers will not widely adopt it unless insurance payers agree to reimburse the cost through established medical billing codes.
What protects it: the moat
It relies on a combination of licensed intellectual property and proprietary algorithms to prevent competitors from replicating its diagnostic software.
Management claims its competitive advantage stems from its patent portfolio and the exclusive license of biomarkers from UCSF. It also utilizes proprietary signal processing to turn raw MRI data into actionable insights.
What growth costs
It must heavily reinvest in clinical trials, physician advocacy, and regulatory efforts to gain the necessary medical and financial market acceptance.
Maintaining the business requires funding ongoing research and development to refine its algorithms. Growth depends on hiring personnel to expand its network of clinicians and spending to secure official medical coding status.
What could damage it
The business will fail if it cannot secure or maintain permanent insurance reimbursement codes, rendering the diagnostic process unaffordable for healthcare providers.
The entire economic model relies on insurers paying for the software usage. If it fails to transition from temporary codes to permanent, reimbursed ones, the customer base will likely abandon the technology due to the lack of financial coverage for the procedure.
About Aclarion, Inc.
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.